Chapter 2 V2R Mutations and Nephrogenic Diabetes Insipidus

Progress in Molecular Biology and Translational Science

Volumn 89, Issue C, 2009, Pages 15-29

  Bichet, Daniel G ^a,b,c  

^a Groupe d'Étude des Protéines Membranaires   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

Author keywords

Dehydration; Mutational analysis; Pharmacological chaperones; Polydipsia; Polyuria; Vasopressin V2 receptor; X linked nephrogenic diabetes insipidus

Indexed keywords

MUTANT PROTEIN; VASOPRESSIN RECEPTOR;

ANIMAL; DRUG ANTAGONISM; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENETICS; HUMAN; METABOLISM; MUTATION; NEPHROGENIC DIABETES INSIPIDUS; PROTEIN FOLDING; PROTEIN TRANSPORT; REVIEW;

ANIMALS; DIABETES INSIPIDUS, NEPHROGENIC; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HUMANS; MUTANT PROTEINS; MUTATION; PROTEIN FOLDING; PROTEIN TRANSPORT; RECEPTORS, VASOPRESSIN;

EID: 77957058673     PISSN: 18771173     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1877-1173(09)89002-9     Document Type: Review

References (66)

1. OMIM (Online Mendelian Inheritance in Man). McKusick-Nathans Institute for Genetic Medicine, Johns Hopkins University (Baltimore, MD) and National Center for Biotechnology Information, National Library of Medicine (Bethesda, MD), 2000 (2000). http://www.ncbi.nlm.nih.gov/omim/ World Wide Web URL:
2. Donaldson Z.R., and Young L.J. Oxytocin, vasopressin, and the neurogenetics of sociality. Science 322 (2008) 900-904
3. Gwee P.C., Amemiya C.T., Brenner S., and Venkatesh B. Sequence and organization of coelacanth neurohypophysial hormone genes: evolutionary history of the vertebrate neurohypophysial hormone gene locus. BMC Evol Biol 8 (2008) 93
4. Venkatesh B., Si-Hoe S.L., Murphy D., and Brenner S. Transgenic rats reveal functional conservation of regulatory controls between the Fugu isotocin and rat oxytocin genes. Proc Natl Acad Sci USA 94 (1997) 12462-12466
5. Tessmar-Raible K., Raible F., Christodoulou F., Guy K., Rembold M., Hausen H., et al. Conserved sensory-neurosecretory cell types in annelid and fish forebrain: insights into hypothalamus evolution. Cell 129 (2007) 1389-1400
6. Thibonnier M., Coles P., Thibonnier A., and Shoham M. The basic and clinical pharmacology of nonpeptide vasopressin receptor antagonists. Annu Rev Pharmacol Toxicol 41 (2001) 175-202
7. Serradeil-Le Gal C., Wagnon J., Valette G., Garcia G., Pascal M., Maffrand J.P., et al. Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands. Prog Brain Res 139 (2002) 197-210
8. Walum H., Westberg L., Henningsson S., Neiderhiser J.M., Reiss D., Igl W., et al. Genetic variation in the vasopressin receptor 1a gene (AVPR1A) associates with pair-bonding behavior in humans. Proc Natl Acad Sci USA 105 (2008) 14153-14156
9. Birnbaumer M., Seibold A., Gilbert S., Ishido M., Barberis C., Antaramian A., et al. Molecular cloning of the receptor for human antidiuretic hormone. Nature 357 (1992) 333-335
10. Seibold A., Brabet P., Rosenthal W., and Birnbaumer M. Structure and chromosomal localization of the human antidiuretic hormone receptor gene. Am J Hum Genet 51 (1992) 1078-1083
11. Fredriksson R., Lagerstrom M.C., Lundin L.G., and Schioth H.B. The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol Pharmacol 63 (2003) 1256-1272
12. Perez D.M. The evolutionarily triumphant G-protein-coupled receptor. Mol Pharmacol 63 (2003) 1202-1205
13. Topiol S., and Sabio M. X-ray structure breakthroughs in the GPCR transmembrane region. Biochem Pharmacol 78 (2009) 11-20
14. Rehmann H., Wittinghofer A., and Bos J.L. Capturing cyclic nucleotides in action: snapshots from crystallographic studies. Nat Rev Mol Cell Biol 8 (2007) 63-73
15. Nielsen S., Frokiaer J., Marples D., Kwon T.H., Agre P., and Knepper M.A. Aquaporins in the kidney: from molecules to medicine. Physiol Rev 82 (2002) 205-244
16. Boone M., and Deen P.M. Physiology and pathophysiology of the vasopressin-regulated renal water reabsorption. Pflugers Arch 456 (2008) 1005-1024
17. Nedvetsky P.I., Tamma G., Beulshausen S., Valenti G., Rosenthal W., and Klussmann E. Regulation of aquaporin-2 trafficking. Handb Exp Pharmacol (2009) 133-157
18. Yang B., Bankir L., Gillespie A., Epstein C.J., and Verkman A.S. Urea-selective concentrating defect in transgenic mice lacking urea transporter UT-B. J Biol Chem 277 (2002) 10633-10637
19. Smith C.P. Mammalian urea transporters. Exp Physiol 94 (2009) 180-185
20. Bankir L., Fernandes S., Bardoux P., Bouby N., and Bichet D.G. Vasopressin-V2 receptor stimulation reduces sodium excretion in healthy humans. J Am Soc Nephrol 16 (2005) 1920-1928
21. Morishita T., Tsutsui M., Shimokawa H., Sabanai K., Tasaki H., Suda O., et al. Nephrogenic diabetes insipidus in mice lacking all nitric oxide synthase isoforms. Proc Natl Acad Sci USA 102 (2005) 10616-10621
22. Fleming E.F., Athirakul K., Oliverio M.I., Key M., Goulet J., Koller B.H., et al. Urinary concentrating function in mice lacking EP3 receptors for prostaglandin E2. Am J Physiol 275 (1998) F955-F961
23. Sands J.M., Naruse M., Baum M., Jo I., Hebert S.C., Brown E.M., et al. Apical extracellular calcium/polyvalent cation-sensing receptor regulates vasopressin-elicited water permeability in rat kidney inner medullary collecting duct. J Clin Invest 99 (1997) 1399-1405
24. Bichet D.G., and Fujiwara T.M. Nephrogenic diabetes insipidus. In: Scriver C.R., Beaudet A.L., Sly W.S., Vallee D., Childs B., Kinzler K.W., and Vogelstein B. (Eds). The metabolic and molecular bases of inherited disease (2001), McGraw-Hill, New York 4181-4204
25. Arthus M.-F., Lonergan M., Crumley M.J., Naumova A.K., Morin D., De Marco L., et al. Report of 33 novel AVPR2 mutations and analysis of 117 families with X-linked nephrogenic diabetes insipidus. J Am Soc Nephrol 11 (2000) 1044-1054
26. Bichet D.G., Arthus M.-F., Lonergan M., Hendy G.N., Paradis A.J., Fujiwara T..M., et al. X-linked nephrogenic diabetes insipidus mutations in North America and the Hopewell hypothesis. J Clin Invest 92 (1993) 1262-1268
27. Perry T.L., Robinson G.C., Teasdale J.M., and Hansen S. Concurrence of cystathioninuria, nephrogenic diabetes insipidus and severe anemia. N Engl J Med 276 (1967) 721-725
28. Arthus M.F., Lonergan M., Fujiwara T.M., and Bichet D.G. Clinical and genetic approaches to the diagnosis of congenital polyuro-polydipsic syndromes. The NDI Foundation 2004 Global Conference (2004), Phoenix, Arizona 55
29. Spanakis E., Milord E., and Gragnoli C. AVPR2 variants and mutations in nephrogenic diabetes insipidus: review and missense mutation significance. J Cell Physiol 217 (2008) 605-617
30. Knops N.B., Bos K.K., Kerstjens M., van Dael K., and Vos Y.J. Nephrogenic diabetes insipidus in a patient with L1 syndrome: a new report of a contiguous gene deletion syndrome including L1CAM and AVPR2. Am J Med Genet A 146A (2008) 1853-1858
31. Fujimoto M., Imai K., Hirata K., Kashiwagi R., Morinishi Y., Kitazawa K., et al. Immunological profile in a family with nephrogenic diabetes insipidus with a novel 11 kb deletion in AVPR2 and ARHGAP4 genes. BMC Med Genet 9 (2008) 42
32. Bichet D.G., Birnbaumer M., Lonergan M., Arthus M.-F., Rosenthal W., Goodyer P., et al. Nature and recurrence of AVPR2 mutations in X-linked nephrogenic diabetes insipidus. Am J Hum Genet 55 (1994) 278-286
33. Hobbs H.H., Russell D.W., Brown M.S., and Goldstein J.L. The LDL receptor locus in familial hypercholesterolemia: mutational analysis of a membrane protein. Annu Rev Genet 24 (1990) 133-170
34. Barak L.S., Salahpour A., Zhang X., Masri B., Sotnikova T.D., Ramsey A.J., et al. Pharmacological characterization of membrane-expressed human trace amine-associated receptor 1 (TAAR1) by a bioluminescence resonance energy transfer cAMP biosensor. Mol Pharmacol 74 (2008) 585-594
35. Morello J.P., Salahpour A., Laperrière A., Bernier V., Arthus M.-F., Lonergan M., et al. Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants. J Clin Invest 105 (2000) 887-895
36. Bernier V., Lagace M., Lonergan M., Arthus M.F., Bichet D.G., and Bouvier M. Functional rescue of the constitutively internalized V2 vasopressin receptor mutant R137H by the pharmacological chaperone action of SR49059. Mol Endocrinol 18 (2004) 2074-2084
37. Hermosilla R., Oueslati M., Donalies U., Schonenberger E., Krause E., Oksche A., et al. Disease-causing V(2) vasopressin receptors are retained in different compartments of the early secretory pathway. Traffic 5 (2004) 993-1005
38. Wuller S., Wiesner B., Loffler A., Furkert J., Krause G., Hermosilla R., et al. Pharmacochaperones post-translationally enhance cell surface expression by increasing conformational stability of wild-type and mutant vasopressin V2 receptors. J Biol Chem 279 (2004) 47254-47263
39. Robben J.H., and Deen P.M. Pharmacological chaperones in nephrogenic diabetes insipidus: possibilities for clinical application. BioDrugs 21 (2007) 157-166
40. Schoneberg T., Schulz A., Biebermann H., Hermsdorf T., Rompler H., and Sangkuhl K. Mutant G-protein-coupled receptors as a cause of human diseases. Pharmacol Ther 104 (2004) 173-206
41. Romisch K. A cure for traffic jams: small molecule chaperones in the endoplasmic reticulum. Traffic 5 (2004) 815-820
42. Conn P.M., and Janovick J.A. Trafficking and quality control of the gonadotropin releasing hormone receptor in health and disease. Mol Cell Endocrinol 299 (2009) 137-145
43. Tamarappoo B.K., and Verkman A.S. Defective aquaporin-2 trafficking in nephrogenic diabetes insipidus and correction by chemical chaperones. J Clin Invest 101 (1998) 2257-2267
44. Kunchaparty S., Palcso M., Berkman J., Velazquez H., Desir G.V., Bernstein P., et al. Defective processing and expression of thiazide-sensitive Na-Cl cotransporter as a cause of Gitelman's syndrome. Am J Physiol 277 (1999) F643-F649
45. Peters M., Ermert S., Jeck N., Derst C., Pechmann U., Weber S., et al. Classification and rescue of ROMK mutations underlying hyperprostaglandin E syndrome/antenatal Bartter syndrome. Kidney Int 64 (2003) 923-932
46. Hayama A., Rai T., Sasaki S., and Uchida S. Molecular mechanisms of Bartter syndrome caused by mutations in the BSND gene. Histochem Cell Biol 119 (2003) 485-493
47. Chillaron J., Estevez R., Samarzija I., Waldegger S., Testar X., Lang F., et al. An intracellular trafficking defect in type I cystinuria rBAT mutants M467T and M467K. J Biol Chem 272 (1997) 9543-9549
48. Bonnardeaux A., and Bichet D.G. Inherited disorders of the renal tubule. In: Brenner B.M. (Ed). Brenner & rector's the kidney (2004), Saunders, Philadelphia 1697-1741
49. Perucca J., Bichet D.G., Bardoux P., Bouby N., and Bankir L. Sodium excretion in response to vasopressin and selective vasopressin receptor antagonists. J Am Soc Nephrol 19 (2008) 1721-1731
50. Lomas D.A., Evans D.L., Finch J.T., and Carrell R.W. The mechanism of Z alpha 1-antitrypsin accumulation in the liver. Nature 357 (1992) 605-607
51. Lawless M.W., Greene C.M., Mulgrew A., Taggart C.C., O'Neill S.J., and McElvaney N.G. Activation of endoplasmic reticulum-specific stress responses associated with the conformational disease Z alpha 1-antitrypsin deficiency. J Immunol 172 (2004) 5722-5726
52. Cohen F.E., and Kelly J.W. Therapeutic approaches to protein-misfolding diseases. Nature 426 (2003) 905-909
53. Ulloa-Aguirre A., Janovick J.A., Brothers S.P., and Conn P.M. Pharmacologic rescue of conformationally-defective proteins: implications for the treatment of human disease. Traffic 5 (2004) 821-837
54. Barak L.S., Oakley R.H., Laporte S.A., and Caron M.G. Constitutive arrestin-mediated desensitization of a human vasopressin receptor mutant associated with nephrogenic diabetes insipidus. Proc Natl Acad Sci USA 98 (2001) 93-98
55. Bernier V., Morello J.P., Zarruk A., Debrand N., Salahpour A., Lonergan M., et al. Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus. J Am Soc Nephrol 17 (2006) 232-243
56. Glover D.J., Lipps H.J., and Jans D.A. Towards safe, non-viral therapeutic gene expression in humans. Nat Rev Genet 6 (2005) 299-310
57. Sangkuhl K., Schulz A., Rompler H., Yun J., Wess J., and Schoneberg T. Aminoglycoside-mediated rescue of a disease-causing nonsense mutation in the V2 vasopressin receptor gene in vitro and in vivo. Hum Mol Genet 13 (2004) 893-903
58. Mankin A.S., and Liebman S.W. Baby, don't stop!. Nat Genet 23 (1999) 8-10
59. Feldman B.J., Rosenthal S.M., Vargas G.A., Fenwick R.G., Huang E.A., Matsuda-Abedini M., et al. Nephrogenic syndrome of inappropriate antidiuresis. N Engl J Med 352 (2005) 1884-1890
60. Decaux G., Vandergheynst F., Bouko Y., Parma J., Vassart G., and Vilain C. Nephrogenic syndrome of inappropriate antidiuresis in adults: high phenotypic variability in men and women from a large pedigree. J Am Soc Nephrol 18 (2007) 606-612
61. Soule S., Florkowski C., Potter H., Pattison D., Swan M., Hunt P., et al. Intermittent severe, symptomatic hyponatraemia due to the nephrogenic syndrome of inappropriate antidiuresis. Ann Clin Biochem 45 (2008) 520-523
62. Marcialis M.A., Faa V., Fanos V., Puddu M., Pintus M.C., Cao A., et al. Neonatal onset of nephrogenic syndrome of inappropriate antidiuresis. Pediatr Nephrol 23 (2008) 2267-2271
63. Kalenga K., Persu A., Goffin E., Lavenne-Pardonge E., van Cangh P.J., Bichet D.G., et al. Intrafamilial phenotype variability in nephrogenic diabetes insipidus. Am J Kidney Dis 39 (2002) 737-743
64. Kocan M., See H.B., Sampaio N.G., Eidne K.A., Feldman B.J., and Pfleger K.D. Agonist-independent interactions between beta-arrestins and mutant vasopressin type II receptors associated with nephrogenic syndrome of inappropriate antidiuresis. Mol Endocrinol 23 (2009) 559-571
65. Tesmer J.J., Sunahara R.K., Gilman A.G., and Sprang S.R. Crystal structure of the catalytic domains of adenylyl cyclase in a complex with Gsalpha.GTPgammaS. Science 278 (1997) 1907-1916
66. Mouillac B., Chini B., Balestre M.N., Elands J., Trumpp-Kallmeyer S., Hoflack J., et al. The binding site of neuropeptide vasopressin V1a receptor. Evidence for a major localization within transmembrane regions. J Biol Chem 270 (1995) 25771-25777